STAT

Listen: Drug pricing partisanship, tech’s march into health care, and Tinder for clinical trials

Has drug price reform already stalled? How far has tech come in medicine? All that and more on the new episode of our #biotech #podcast, "The Readout LOUD."

Has drug price reform already stalled? How far has tech come in medicine? And should there be an app for ?

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A GLP-1 Side Effect, U.K. Clinical Trial Transparency, And More
A new study links GLP-1 drugs like Ozempic to a higher risk of aspiration pneumonia — a lung infection caused by food breathed into the lungs — after endoscopies.
STAT1 min read
STAT+: Medicare Expected To Negotiate Obesity Drug Prices Soon, New Analysis Predicts
Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An AstraZeneca Deal, A WHO Pandemic Pact, And More
AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on targeted radiation therapies for cancer.

Related Books & Audiobooks